Tim Springer (Harvard)

With Mod­er­na wind­fall, Har­vard pro­fes­sor and in­te­grins leg­end Tim Springer do­nates $210M to his In­sti­tute for Pro­tein In­no­va­tion

Tim Springer, with his name sta­pled to the likes of Mod­er­na, Schol­ar Rock and Ed­i­tas Med­i­cine, plus the foun­da­tion­al work for Take­da’s ul­cer­a­tive col­i­tis and Crohn’s dis­ease med En­tyvio, has had a lot on his plate over the past five decades.

In 2020, the Har­vard pro­fes­sor be­came a bil­lion­aire thanks to ear­ly in­vest­ing in Mod­er­na and hav­ing prof­it­ed a cou­ple hun­dred mil­lion ear­li­er in his ca­reer off his com­pa­ny LeukoSite’s sale to Mil­len­ni­um Phar­ma­ceu­ti­cals be­fore the turn of the cen­tu­ry.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.